Codexis to Report First Quarter 2026 Financial Results on May 7
Rhea-AI Summary
Codexis (NASDAQ: CDXS) will report Q1 2026 financial results on May 7, 2026 after market close. Management will host a conference call and webcast at 4:30 PM ET to discuss results and provide a business update. The live webcast will be archived for 90 days; telephone replay available for 48 hours (Access ID #13726635).
Positive
- None.
Negative
- None.
News Market Reaction – CDXS
In the Apr 23 session, CDXS gained 2.02%, reflecting a moderate positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 25 | Earnings date notice | Neutral | +1.4% | Scheduled Q4 and FY2025 results call on March 11 with webcast details. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior earnings-date scheduling news led to a modest positive move of 1.36%, suggesting these announcements have historically had limited but positive impact.
Over recent months, Codexis reported strong Q4 and fiscal 2025 results with revenue of $70.4M and cash of $78.2M, driving a 34.65% move. Operationally, it signed a deal to manufacture 50 grams of siRNA using its ECO Synthesis platform and achieved ISO 9001:2015 certification. The company also regularly communicates around conferences and earnings dates. Today’s announcement fits that pattern as it simply schedules the upcoming Q1 2026 earnings release and call.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the first quarter of 2026 on Thursday, May 7, 2026, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company’s financial results and provide a business update.
Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (international). A telephone replay of the call will be available for 48 hours by dialing 877-660-6853 (domestic) or 201-612-7415 (international), access ID #13726635.
About Codexis
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis® manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com.
For More Information
Investor Contact
Georgia Erbez
(650) 421-8100
ir@codexis.com
